Literature DB >> 27241258

Targeting the IFN-γ/CXCL10 pathway in lichen planus.

Vito Di Lernia1.   

Abstract

Lichen planus is a chronic inflammatory disease of the skin, mucous membranes and nails. Management of oral involvement, particularly atrophic and erosive lesions, is challenging. Noteworthy, there is a lack of published evidence for treatment. Cell-mediated cytotoxicity is actually regarded as a major mechanism of pathogenesis. The interferon-gamma induced chemokines CXCL10 and CXCL9 are strongly expressed in serum of patients as well as in both skin and mucosal lesions. Therefore the interferon gamma/CXCL10 axis is considered a key process for both progression and maintenance of chronic cytotoxic inflammation. According to these findings, the interferon gamma/CXCL10 axis could be considered a therapeutically attractive target to reverse inflammation. Since interferon gamma signal transduction occurs through JAK 1 and 2, JAK inhibitors could lead to blockade of interferon gamma signaling and downstream CXCL10 expression.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27241258     DOI: 10.1016/j.mehy.2016.04.042

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  3 in total

Review 1.  JAK inhibitors in dermatology: The promise of a new drug class.

Authors:  William Damsky; Brett A King
Journal:  J Am Acad Dermatol       Date:  2017-01-28       Impact factor: 11.527

Review 2.  The influence of interferon on healthy and diseased skin.

Authors:  Grace A Hile; Johann E Gudjonsson; J Michelle Kahlenberg
Journal:  Cytokine       Date:  2018-12-06       Impact factor: 3.861

3.  Level-Specific Differences in Systemic Expression of Pro- and Anti-Inflammatory Cytokines and Chemokines after Spinal Cord Injury.

Authors:  James Hong; Alex Chang; Mohammad-Masoud Zavvarian; Jian Wang; Yang Liu; Michael G Fehlings
Journal:  Int J Mol Sci       Date:  2018-07-25       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.